The drug maker had reported a net profit of Rs 801 crore in the July-September quarter of last fiscal.

Revenue from operations grew 20% YoY to Rs 5237 crore.

On a quarter-on-quarter (QoQ) basis the net profit declined 35.8% and revenue by 15.6%.

The earnings before interest, tax, depreciation and ammortisation (EBITDA) increased 27.5% YoY to Rs 1461.4 crore. On QoQ, EBITDA dropped 29.9%.

The EBITDA margins for Q1FY25 improved 170 basis points YoY to 27.9%.The company has spent Rs. 301.7 crore on capex for the quarter, while research & development (R&D) investments stood at Rs. 480 crore or 9.2% of revenues.Net cash as on September 30 was Rs. 2590.6 crore.

India business which constitutes 38% of revenues rose 10% YoY to Rs 1944.4 crore in Q2FY25. The formulation business gained 9.2% to Rs 1457 crore.
The branded formulation segment grew 10% outpacing the market growth both in chronic and acute segments.

The company launched 12 new products including line extensions with 4 first-in-India launches, retaining leadership position in the nephrology and oncology segments.

The consumer wellness sales rose 12% to Rs 487.5 crore led by personal care segment and food and nutrition segment.

US formulation business that constitutes 30% of revenue, rose 30% YoY to Rs 2416.8 crore.

The company launched 4 new products during the quarter. The company filed 8 abbreviated new drug applications (ANDAs) and received approval for 9 new products including 3 tentative approvals during the quarter.

Emerging markets and Europe formulation business rose 20% YoY to Rs 539 crore.

The active pharmaceutical ingredient (API) business was down 15% YoY to 119.4 crore.

“We are on course to achieve our growth aspirations for FY25 and are committed to investing in sustainable growth initiatives and innovative solutions for the future,” said Dr. Sharvil Patel, MD of Zydus.